Table 5 Risk of exacerbation or death from Month 6 onwards by CID status at Month 6 in the overall population and by GOLD
From: Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Outcome at Month 6 | Patients with any CID event vs. patients without, HR (95% CI) | Patients with confirmed FEV1 decline vs. patients without, HR (95% CI) | Patients with confirmed SGRQ deterioration vs. patients without, HR (95% CI) | Patients with moderate/severe exacerbation vs. patients without, HR (95% CI) |
|---|---|---|---|---|
Overall population | ||||
Moderate/severe exacerbation | 1.79 (1.67, 1.92) | 1.11 (1.02, 1.22) | 1.30 (1.18, 1.43) | 2.36 (2.20, 2.53) |
Severe exacerbation | 1.67 (1.49, 1.86) | 1.06 (0.92, 1.23) | 1.66 (1.44, 1.91) | 1.88 (1.68, 2.11) |
Death up to Day 1470 | 1.21 (1.06, 1.39) | 1.09 (0.92, 1.31) | 1.27 (1.05, 1.54) | 1.22 (1.05, 1.41) |
GOLD 2 | ||||
Moderate/severe exacerbation | 1.73 (1.56, 1.92) | 1.15 (1.01, 1.30) | 1.24 (1.07, 1.44) | 2.49 (2.23, 2.78) |
Severe exacerbation | 1.58 (1.30, 1.92) | 1.23 (0.97, 1.55) | 1.77 (1.37, 2.27) | 1.79 (1.46, 2.21) |
Death up to Day 1470 | 1.21 (0.95, 1.55) | 1.26 (0.94, 1.68) | 1.36 (0.98, 1.90) | 1.01 (0.75, 1.35) |
GOLD 3 | ||||
Moderate/severe exacerbation | 1.84 (1.67, 2.04) | 1.18 (1.03, 1.35) | 1.32 (1.15, 1.52) | 2.21 (1.99, 2.45) |
Severe exacerbation | 1.69 (1.45, 1.96) | 1.08 (0.88, 1.33) | 1.57 (1.29, 1.92) | 1.79 (1.54, 2.09) |
Death up to Day 1470 | 1.20 (0.99, 1.45) | 1.17 (0.91, 1.51) | 1.30 (1.00, 1.70) | 1.15 (0.94, 1.41) |
GOLD 4 | ||||
Moderate/severe exacerbation | 1.84 (1.47, 2.32) | 1.35 (0.85, 2.15) | 1.57 (1.14, 2.16) | 1.97 (1.55, 2.50) |
Severe exacerbation | 1.69 (1.26, 2.25) | 2.38 (1.46, 3.88) | 1.81 (1.23, 2.67) | 1.46 (1.09, 1.97) |
Death up to Day 1470 | 1.16 (0.84, 1.60) | 1.52 (0.88, 2.63) | 1.00 (0.60, 1.66) | 1.22 (0.87, 1.70) |